Management tracks: Melinta, Lundbeck
Infectious disease company Melinta Therapeutics Inc. (New Haven, Conn.) hired Dan Wechsler as president and CEO and John Bluth as EVP of investor relations and corporate communications. Wechsler was operating partner at Welsh, Carson, Anderson & Stowe, and Bluth was EVP of investor relations and corporate communications at Cempra Inc. (NASDAQ:CEMP). Melinta is acquiring Cempra and will list on NASDAQ. The deal is expected to close this quarter. Melinta also promoted John Temperato to chief commercial officer from president and COO (see BioCentury Extra, Aug. 11).
Neurology company H. Lundbeck A/S (CSE:LUN) named EVP and CFO Anders Götzsche interim CEO. Götzsche succeeds Kåre Schultz, who resigned in September. Schultz is now president and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Staffan Schüberg also resigned as EVP and chief commercial officer of Lundbeck, effective Oct. 31 (see BioCentury Extra, Sept. 11)...